Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01064440 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia
A Phase 2 study, sponsored by Helixmith Co..
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT01064440 is a Phase 2 study that has completed, run by Helixmith Co.. The registered enrollment target is 52 participants.
The verdict
NCT01064440, a Phase 2 study, has completed, sponsored by Helixmith Co..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate whether intramuscular injections of VM202 into the calf is safe and effective in the treatment of critical limb ischemia.
Interventions
- OTHER Placebo
- BIOLOGICAL Low Dose VM202
- BIOLOGICAL High Dose VM202
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2010-07-09 |
| Est. Completion | 2023-11-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01064440
The ClinicalTrials.gov registry entry for NCT01064440 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Helixmith Co., which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01064440 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01064440 about?
NCT01064440 is a clinical study titled "Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia". The purpose of this study is to evaluate whether intramuscular injections of VM202 into the calf is safe and effective in the treatment of critical limb ischemia.
What is the current status of trial NCT01064440?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2010-07-09. Estimated completion is 2023-11-17.
What interventions are being tested in trial NCT01064440?
The interventions under investigation include: Placebo (OTHER), Low Dose VM202 (BIOLOGICAL), High Dose VM202 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01064440?
This trial is sponsored by Helixmith Co., which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.